Abstract
Introduction: SLE is a multisystem autoimmune
disease that can exacerbate and remit. This disease attacks various
organs
such as the skin, kidneys, musculoskeletal, nervous, cardiovascular, and
oral cavities. As many as 50-70% of SLE patients have
kidney problems. Renal involvement is a major cause of high morbidity
and mortality in this population. Clinically, renal disease
in SLE begins with asymptomatic proteinuria which then progresses
rapidly to progressive glomerulonephritis with renal
failure. About 95% of SLE patients can show musculoskeletal
manifestations. Arthralgia, joint deformities, temporomandibular
joint abnormalities and avascular necrosis have been reported in SLE
patients. Systemic lupus erythematosus (Systemic Lupus
Erythematosus / SLE) cannot be cured, but there is a series of active
phases (flares) and the calm phase of the disease. The goals
of available treatment are to reduce the severity of symptoms, prevent
organ damage, and minimize their impact on the life of
people with SLE. The type of drug and dose given to one lupus sufferer
is not the same as other lupus sufferers and can change from
time to time depending on the symptoms you feel and the severity of
them. Therapy in lupus is very individualistic depending on
the severity of the disease, the goal is to suppress disease activity by
weighing the risk of side effects. In life-threatening patients,
therapy is carried out as aggressively as possible by administering very
high doses of the drug and carried out in a hospital. New
therapy is needed in lupus patients so that life expectancy increases,
and complications can be avoided.
Discussion: In recent years, the treatment of LES
nephritis has been based on several years of high doses of
immunosuppressants
and NSAIDs in mild cases. Immunosuppressants used can be metotrexan,
corticosteroids, cyclophosphamide, cyclosporin A,
azatiophrine and mycophenolate mofetil. This kind of approach is usually
used in severe cases such as lupus nephritis by using
several drug combinations. Another therapy for LES is by changing the
lifestyle (lifestyle) by maintaining health with exercise, diet
and vitamins and avoiding predisposing factors such as sunlight.
However, current LES therapy prevents the patient’s condition
from recurring (flare) or worsening and complications occur, it is hoped
that in the future LES therapy can improve the general
condition of the patient so that the patient can recover easily due to
LES.
Conclusion: A new therapy for SLE patients is needed for increasing quality life and maintenance health. Further research is
needed in the new therapy of SLE to improve safety and health condition itself.
Keywords: SLE, autoimmune; therapy
Abbreviations: SLE: Systemic Lupus Erythematosus; AAV: Adeno-Association Virus; EAE: Experimental Allergic Encephalomyelitis;
APS: Antiphospholipid Syndrome
Read More About This Article Please Click on Below Link:
https://lupinepublishers.com/pediatric-dentistry-journal/fulltext/new-therapy-for-systemic-lupus-erythematosus-a-review-article.ID.000228.php
Read More About Lupine Publishers Google Scholar Articles:
https://scholar.google.com/citations?view_op=view_citation&hl=en&user=h1QvhsYAAAAJ&citation_for_view=h1QvhsYAAAAJ:k_IJM867U9cC
